Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Listerine sales

This article was originally published in The Tan Sheet

Executive Summary

Cool mint Listerine PocketPaks retail sales exceeded $175 mil. in first year, placing the portable oral care strips in the top 2% of all new consumer products, Pfizer Consumer Healthcare says. Other oral care products in top position include Colgate Total, Crest WhiteStrips, firm notes. Pfizer sold over 200 mil. PocketPaks in first year on shelves; introduction is credited with reinvigorating the 120-year-old brand. Backed with a $40 mil. ad campaign, PocketPaks were expected to exceed $100 mil. in first year sales after launching in October 2001 (1"The Tan Sheet" Oct. 15, 2001, In Brief)...

You may also be interested in...



Warner-Lambert

First-year sales of Cool Mint Listerine PocketPaks strips, which launched nationwide Oct. 9, expected to exceed $100 mil., company says. W-L and ad agency J. Walter Thompson (New York) plan to launch $40 mil. campaign including TV, other mediums within next few weeks (1"The Tan Sheet" July 9, p. 4). PocketPaks, which kill odor-causing mouth germs, received promotional support from network TV's Regis & Kelly show when exuberant co-host Kelly Ripa tried strips on air and gave them an enthusiastic review. Over the last few months, W-L has sent free samples to several TV stations, professional sports teams and modeling agencies across the country, firm says

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel